Cargando…
Over-the-counter Dispensing: Widening Access to Inhaled Corticosteroid/Formoterol Reliever Therapy
Autores principales: | Beasley, Richard, Hatter, Lee |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Thoracic Society
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9940135/ https://www.ncbi.nlm.nih.gov/pubmed/36548806 http://dx.doi.org/10.1164/rccm.202212-2297ED |
Ejemplares similares
-
ICS-formoterol reliever versus ICS and short-acting β(2)-agonist reliever in asthma: a systematic review and meta-analysis
por: Hatter, Lee, et al.
Publicado: (2021) -
Asthma control with ICS-formoterol reliever versus maintenance ICS and SABA reliever therapy: a post hoc analysis of two randomised controlled trials
por: Hatter, Lee, et al.
Publicado: (2022) -
Efficacy of budesonide/formoterol maintenance and reliever therapy compared with higher-dose budesonide as step-up from low-dose inhaled corticosteroid treatment
por: Jenkins, Christine R., et al.
Publicado: (2017) -
The Children's Anti-inflammatory Reliever (CARE) study: a protocol for a randomised controlled trial of budesonide-formoterol as sole reliever therapy in children with mild asthma
por: Hatter, Lee, et al.
Publicado: (2021) -
Inhaled Anesthetics for Sedation in ICU: Widening Horizons!
por: Krishna, Bhuvana
Publicado: (2022)